AR029432A1 - Derivados de imidazol 1-sustituido que poseen afinidad con los alfa2-adrenorreceptores, uso de dichos derivados como medicamentos y/o para la preparacion de composiciones farmaceuticas formuladas con dichos compuestos de 1-imidazol sustituido, proceso para preparar dichos derivados - Google Patents
Derivados de imidazol 1-sustituido que poseen afinidad con los alfa2-adrenorreceptores, uso de dichos derivados como medicamentos y/o para la preparacion de composiciones farmaceuticas formuladas con dichos compuestos de 1-imidazol sustituido, proceso para preparar dichos derivadosInfo
- Publication number
- AR029432A1 AR029432A1 ARP010100140A ARP010100140A AR029432A1 AR 029432 A1 AR029432 A1 AR 029432A1 AR P010100140 A ARP010100140 A AR P010100140A AR P010100140 A ARP010100140 A AR P010100140A AR 029432 A1 AR029432 A1 AR 029432A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- derivatives
- imidazol
- halo
- cycloalkyl
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000008569 process Effects 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 9
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 2
- -1 1,2,3,4-tetrahydronaphthyl Chemical group 0.000 abstract 2
- 108060003345 Adrenergic Receptor Proteins 0.000 abstract 2
- 102000017910 Adrenergic receptor Human genes 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 abstract 1
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 208000001089 Multiple system atrophy Diseases 0.000 abstract 1
- 206010031127 Orthostatic hypotension Diseases 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 150000002460 imidazoles Chemical class 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 125000006413 ring segment Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se describen y reivindican compuestos de imidazol de formula (1) donde X es ûCH2(CH2)p-, -O-, =NH o ûS-; R1 es fenilo, naftilo, 1,2,3,4-tetrahidronaftilo, C3-7-cicloalquilo, C5-7-cicloalquinilo o grupo heterocíclico parcialmente o completamente saturado aromático mono o bicíclico con 5 a 10 átomos anillo que consisten de átomos de carbono y uno a tres heteroátomos seleccionados de N, O y S; donde dicho fenilo, naftilo, 1,2,3,4-tetrahidronaftilo, C3-7-cicloalquilo, C5-7-cicloalquilo o grupo heterocíclico parcialmente o completamente saturado aromático mono o bicíclico es opcionalmente sustituido con uno a tres sustituyentes seleccionados independientemente de halogeno ûOH, -NH2, halo-C1-6-alquilo, C1-6-alquilo, C2-6-alquenilo, C2-6-alquinilo, C1-6-alcoxi, OH-(C1-6)-alquilo, NH2-(C1-6)-alquilo y mono o di(C1-6-alquilo)amino; R2 es H o C1-6-alquilo; R3 es H o C1-6 alquilo, y R4 es H o C1-6-alquilo; R5 H o R5 y R7 juntos forman una union; Cada R6 es independientemente halogeno, -OH, -NH2, Halo ûC1-6-alquilo, C1-6-alquilo, C1-6-alcoxi u OH-(C1-6)-alquilo; R7 es H, OH o C1-4-alquilo o R7 y R5 juntos forman una union; Cada R8 es independientemente OH, C1-6-alquilo, Halo-C1-C6-alquilo, C1-6-alcoxi; m es 0, 1, 2 o 3;n es 0 o 1; p es 0 o 1; r es 0 o 1; t es 0 1, o 2; ésteres o sales farmacéuticamente aceptables de los mismos. Los compuestos mencionados son utiles, en vista de su afinidad con los adrenorreceptores alfa 2 en el tratamiento de enfermedades y desordenes relacionados con dichos adrenorreceptores, v.gr.: desordenes del sistema periférico central (SNC); desordenes neurologicos, psiquiátricos, cognitivos, diabetes, disfuncion sexual, hipotension ortostática. También se reivindican los objetos restantes mencionados en el título.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20000073A FI20000073A0 (fi) | 2000-01-14 | 2000-01-14 | Uusia imidatsolijohdannaisia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR029432A1 true AR029432A1 (es) | 2003-06-25 |
Family
ID=8557065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010100140A AR029432A1 (es) | 2000-01-14 | 2001-01-12 | Derivados de imidazol 1-sustituido que poseen afinidad con los alfa2-adrenorreceptores, uso de dichos derivados como medicamentos y/o para la preparacion de composiciones farmaceuticas formuladas con dichos compuestos de 1-imidazol sustituido, proceso para preparar dichos derivados |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP1261588B1 (es) |
| JP (1) | JP2003519688A (es) |
| KR (1) | KR20020084091A (es) |
| CN (1) | CN1187336C (es) |
| AR (1) | AR029432A1 (es) |
| AT (1) | ATE280161T1 (es) |
| AU (1) | AU769896B2 (es) |
| BR (1) | BR0107644A (es) |
| CA (1) | CA2397283A1 (es) |
| CZ (1) | CZ20022358A3 (es) |
| DE (1) | DE60106572T2 (es) |
| DK (1) | DK1261588T3 (es) |
| EE (1) | EE200200389A (es) |
| ES (1) | ES2228884T3 (es) |
| FI (1) | FI20000073A0 (es) |
| GC (1) | GC0000218A (es) |
| HK (1) | HK1049999B (es) |
| HU (1) | HUP0301008A3 (es) |
| IL (1) | IL150506A0 (es) |
| MX (1) | MXPA02006872A (es) |
| NO (1) | NO323117B1 (es) |
| NZ (1) | NZ519919A (es) |
| PE (1) | PE20011230A1 (es) |
| PL (1) | PL207281B1 (es) |
| PT (1) | PT1261588E (es) |
| RU (1) | RU2265598C2 (es) |
| SI (1) | SI1261588T1 (es) |
| SK (1) | SK286320B6 (es) |
| WO (1) | WO2001051472A1 (es) |
| ZA (1) | ZA200205301B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI20002756A0 (fi) * | 2000-12-15 | 2000-12-15 | Orion Yhtymae Oyj | Uusi hoitomenetelmä |
| TW200930291A (en) * | 2002-04-29 | 2009-07-16 | Bayer Cropscience Ag | Pesticidal heterocycles |
| FI20022159A0 (fi) | 2002-12-05 | 2002-12-05 | Orion Corp | Uusia farmaseuttisia yhdisteitä |
| DE102004035322A1 (de) * | 2004-07-21 | 2006-02-16 | Universität des Saarlandes | Selektive Hemmstoffe humaner Corticoidsynthasen |
| ES2381589T3 (es) | 2006-10-19 | 2012-05-29 | F. Hoffmann-La Roche Ag | Aminometil-4-imidazoles |
| KR101134226B1 (ko) * | 2006-11-16 | 2012-04-10 | 에프. 호프만-라 로슈 아게 | 치환된 4-이미다졸 |
| US20080146523A1 (en) | 2006-12-18 | 2008-06-19 | Guido Galley | Imidazole derivatives |
| AR090557A1 (es) * | 2012-04-02 | 2014-11-19 | Orion Corp | DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2225782A (en) * | 1988-12-09 | 1990-06-13 | Farmos Group Limited | Imidazole derivatives useful for treatment of diabetes |
| GB2244431A (en) * | 1990-05-31 | 1991-12-04 | Farmos Oy | Treatment of age related memory impairment and other cognitive disorders |
| US5541211A (en) * | 1991-06-18 | 1996-07-30 | Orion-Yhtyma Oy | Administration of atipamezole to elicit a yohimbine-like alpha-adrenoreceptor antagonistic noradrenergic transmission |
| GB9113077D0 (en) * | 1991-06-18 | 1991-08-07 | Orion Yhtymae Oy | Use of atipamezole |
| GB9127050D0 (en) * | 1991-12-20 | 1992-02-19 | Orion Yhtymae Oy | Substituted imidazole derivatives and their preparation and use |
| GB9520150D0 (en) * | 1995-10-03 | 1995-12-06 | Orion Yhtymae Oy | New imidazole derivatives |
| RU2235092C2 (ru) * | 1997-12-04 | 2004-08-27 | Оллерган Инк. | Замещенные производные имидазола, способ введения активного соединения и способ лечения на основе этих соединений |
| US6503935B1 (en) * | 1998-08-07 | 2003-01-07 | Abbott Laboratories | Imidazoles and related compounds as α1A agonists |
| TWI283669B (en) * | 1999-06-10 | 2007-07-11 | Allergan Inc | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors |
-
2000
- 2000-01-14 FI FI20000073A patent/FI20000073A0/fi unknown
-
2001
- 2001-01-10 GC GCP20011133 patent/GC0000218A/en active
- 2001-01-12 PT PT01942360T patent/PT1261588E/pt unknown
- 2001-01-12 SK SK998-2002A patent/SK286320B6/sk not_active IP Right Cessation
- 2001-01-12 AR ARP010100140A patent/AR029432A1/es unknown
- 2001-01-12 EP EP01942360A patent/EP1261588B1/en not_active Expired - Lifetime
- 2001-01-12 MX MXPA02006872A patent/MXPA02006872A/es active IP Right Grant
- 2001-01-12 DE DE60106572T patent/DE60106572T2/de not_active Expired - Lifetime
- 2001-01-12 AU AU28532/01A patent/AU769896B2/en not_active Ceased
- 2001-01-12 JP JP2001551854A patent/JP2003519688A/ja active Pending
- 2001-01-12 IL IL15050601A patent/IL150506A0/xx not_active IP Right Cessation
- 2001-01-12 RU RU2002121777/04A patent/RU2265598C2/ru not_active IP Right Cessation
- 2001-01-12 HU HU0301008A patent/HUP0301008A3/hu unknown
- 2001-01-12 CN CNB018037194A patent/CN1187336C/zh not_active Expired - Fee Related
- 2001-01-12 WO PCT/FI2001/000030 patent/WO2001051472A1/en not_active Ceased
- 2001-01-12 PE PE2001000029A patent/PE20011230A1/es not_active Application Discontinuation
- 2001-01-12 PL PL356884A patent/PL207281B1/pl not_active IP Right Cessation
- 2001-01-12 AT AT01942360T patent/ATE280161T1/de not_active IP Right Cessation
- 2001-01-12 CZ CZ20022358A patent/CZ20022358A3/cs unknown
- 2001-01-12 BR BR0107644-2A patent/BR0107644A/pt not_active Application Discontinuation
- 2001-01-12 HK HK03102023.4A patent/HK1049999B/zh not_active IP Right Cessation
- 2001-01-12 DK DK01942360T patent/DK1261588T3/da active
- 2001-01-12 SI SI200130256T patent/SI1261588T1/xx unknown
- 2001-01-12 ES ES01942360T patent/ES2228884T3/es not_active Expired - Lifetime
- 2001-01-12 NZ NZ519919A patent/NZ519919A/en unknown
- 2001-01-12 CA CA002397283A patent/CA2397283A1/en not_active Abandoned
- 2001-01-12 EE EEP200200389A patent/EE200200389A/xx unknown
- 2001-01-12 KR KR1020027009037A patent/KR20020084091A/ko not_active Ceased
-
2002
- 2002-07-02 ZA ZA200205301A patent/ZA200205301B/xx unknown
- 2002-07-08 NO NO20023298A patent/NO323117B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2111650T3 (es) | Derivados aciclicos de etilenodiamina como antagonistas de receptores de la sustancia p. | |
| YU128091A (sh) | Derivati hinuklidina | |
| ECSP22012347A (es) | Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr | |
| AR079541A1 (es) | Compuestos sustituidos de n-(1h-indazol-4-il) imidazo (1,2-a) piridin-3-carboxamida como inhibidores de cfms | |
| PE20020721A1 (es) | Derivados de quinuclidina como agentes antimuscarinicos m3 | |
| EA200001171A1 (ru) | Бициклические пиримидины и бициклические 3,4-дигидропиримидины как ингибиторы клеточной пролиферации | |
| PE20020381A1 (es) | COMPUESTOS DE PIRROLO[2,3-d]PIRIMIDINA COMO INHIBIDORES DE LA PROTEINA QUINASA | |
| AR004320A1 (es) | Nuevos compuestos de pirimidina condensados biciclicos; un procedimiento para su preparacion; composiciones farmaceuticas que los contienen y su usocomo agentes terapeuticos, en particular como inhibidores de la tirosina quinasa. | |
| EA200500342A1 (ru) | Гетероциклические замещённые пиперазины для лечения шизофрении | |
| PE20020911A1 (es) | Derivados de indol como agonistas de 5ht2 | |
| AR033678A1 (es) | Derivados de quinolina, procedimiento para prepararlos, uso de los mismos para la preparacion de medicamentos y los medicamentos que contienen dichos derivados | |
| ES2064665T3 (es) | Mejoras en y en relacion con antagonistas de angiotensina ii. | |
| PE20231372A1 (es) | Compuestos heterociclicos | |
| AR015595A1 (es) | Compuestos derivados de pirazolo [4,3-d]-pirimidin-7-onas, composiciones farmaceuticas, formulacion veterinaria, uso de dichos compuestos en la preparacionde composicion y formulaciones. procedimientos para su uso, compuestos intermediarios, proceso para la preparacion de los compuestos. | |
| UY24546A1 (es) | Derivados indolicos utiles para terapia | |
| SE9702564D0 (sv) | New compounds | |
| AR029432A1 (es) | Derivados de imidazol 1-sustituido que poseen afinidad con los alfa2-adrenorreceptores, uso de dichos derivados como medicamentos y/o para la preparacion de composiciones farmaceuticas formuladas con dichos compuestos de 1-imidazol sustituido, proceso para preparar dichos derivados | |
| ATE348101T1 (de) | Carbolin derivate als hemmstoffe von phospphodiesterase 5 (pde5) zur behandlung kardiovaskulärer erkrankungen und der erektilen dysfunktion | |
| ES2038707T3 (es) | Procedimiento para la obtencion de enantiomeros (+) y (-) de derivados de la 3,4-dihidro-2h-(1)-benzopiran-3-amina. | |
| ES2078267T3 (es) | H-heteroaril-purin-6-aminas, un procedimiento para su preparacion y su uso como medicamentos. | |
| AR037347A1 (es) | Derivados de triazol | |
| SE9702563D0 (sv) | Compounds | |
| PA8533501A1 (es) | Derivados de pirimidina 2,4,5-trisustituida | |
| UY27998A1 (es) | Piperazinas sustituidas sustituidas heterocíclicas para el tratamiento de la esquizofrenia | |
| AR036108A1 (es) | Derivados de oxadiazol, respectivamente de tiadiazol-pirrolidina, uso de dichos derivados en la preparacion de composiciones para modular, bloquear o antagonizar la actividad de oxitocina con sus receptores y/o el tratamiento y/o prevencion de enfermedades mediadas por la oxitocina , inclusive en la |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |